KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Telmisartan 20 mg/S-Amlodipine 2.5 mg versus Telmisartan 40 mg in Patients with Hypertension, Inadequately Controlled on Telmisartan 20 mg Monotherapy: A Randomized, Double-Blind, Multicenter, Phase 3 Trial.

Jong-Chan Youn, Eui-Soon Kim, Tae Ho Park, Young Soo Lee, Soon Jun Hong, Jin-Yong Hwang, Jung-Kyu Han, Jung-Woo Son, Chan Joo Lee, Jung Hyun Choi, Sung Uk Kwon, Seok Yeon Kim, Hwan-Cheol Park, Seung-Hyuk Choi

Drug Des Devel Ther 20 587488

PMID42199811
PMCIDPMC13199865
DOI10.2147/DDDT.S587488
发表日期2026-05-27
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 7 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 1:研究设计图;Figure 2:CONSORT/入组流程图;Figure 3:非 KM 图;Figure 4:AI 判定为 other;另有 2 张未列出。
摘要

摘要

PURPOSE: This 8-week, randomized, double-blind study evaluated the efficacy and safety of low-dose combination of telmisartan 20 mg/S-amlodipine 2.5 mg (T20/SA2.5) versus telmisartan 40 mg (T40) monotherapy in patients with essential hypertension inadequately controlled on T20. PATIENTS AND METHODS: After a 4-week run-in period with T20 (baseline), patients with uncontrolled blood pressure (BP) were randomized (1:1) to T20/SA2.5 or T40 for 8 weeks. The primary endpoint was the change in mean sitting systolic blood pressure (MSSBP) from baseline to week 8. Secondary endpoints included changes in MSSBP and mean sitting diastolic blood pressure (MSDBP) at weeks 4 and 8, BP control rate, response rate (≥20 mmHg reduction in MSSBP and ≥10 mmHg in MSDBP), and treatment-emergent adverse events (TEAEs). RESULTS: Overall, 108 patients were randomized. At week 8, least squares (LS) mean (standard error [SE]) reduction in MSSBP from baseline was greater with T20/SA2.5 than with T40 (-16.97 [2.06] mmHg vs. -7.42 [2.04] mmHg; P<0.001). LS mean (SE) reductions in MSDBP at week 8 were also greater with T20/SA2.5 than with T40 (-7.98 [1.17] mmHg vs. -4.01 [1.15] mmHg; P=0.006). The BP control rate was significantly higher with T20/SA2.5 than with T40 (53.70% vs. 29.63%; P=0.010); the response rate was numerically higher with T20/SA2.5 (12.96% vs. 5.56%; P=0.182). The incidence of TEAEs was lower with T20/SA2.5 than with T40 (9.26% vs. 20.37%, P=0.104); most events were mild. CONCLUSION: T20/SA2.5 demonstrated superior BP-lowering efficacy and favorable tolerability compared with T40 in patients inadequately controlled on T20, supporting the value of early low-dose combination therapy.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1无图注
非 KM Figure
Figure 1Study design.
非 KM Figure
Figure 2Patient disposition. Flow diagram illustrating the study population from screening and randomization, including those who discontinued with specific reasons, through to the analysis populations: Safety set, Full Analysis Set, and Per-Protocol Set T20/SA2.5, telmisartan 20 mg/S-amlodipine 2.5 mg; T40, telmisartan 40 mg.
非 KM Figure
Figure 3LS-mean changes in sitting systolic (MSSBP) and diastolic blood pressure (MSDBP) from baseline to Weeks 4 and 8 with telmisartan 20 mg/S-amlodipine 2.5 mg (T20/SA2.5) or telmisartan 40 mg (T40).*P < 0.05 vs. baseline; †P < 0.05 vs. telmisartan 40 mg.
非 KM Figure
Figure 4Mean change from baseline in ( A ) sitting systolic blood pressure (SBP) and ( B ) sitting diastolic blood pressure (DBP) at weeks 4 and 8. *P < 0.05 vs. baseline (paired t -test or Wilcoxon signed rank test); †P < 0.05 vs. telmisartan 40 mg (ANCOVA adjusted for baseline MSSBP strata: <140, 140–159, ≥160 mmHg).
非 KM Figure
Figure 5( A ) Control and ( B ) Response rate of Telmisartan 20 mg/S-amlodipine 2.5 mg compared with telmisartan 40 mg at Weeks 4 and 8 from baseline.
非 KM Figure
Figure 6Forest plot of between-group differences in the change from baseline to Week 8 in mean sitting systolic blood pressure (MSSBP) across subgroups. Squares represent LS-mean differences; horizontal bars indicate 95% confidence intervals. Negative values favor T20/SA2.5 (greater reduction in MSSBP).
非 KM Figure